|
Alternative names, keywords |
|
|
Samples required |
● Clotted blood (gold cap, 5 mL tube). Smaller tubes are available for paediatric samples. Sample should be taken 8 - 12 hours after last dose. 7 days to steady state. |
|
Test indications |
Routine monitoring of serum digoxin concentrations is not recommended. A digoxin concentration measured within 8 to 12 hours of the last dose may be useful to confirm a clinical impression of toxicity or non‑adherence. |
|
Factors affecting test performance/ results |
Digoxin-like immunoreactive substances (DLIS) have been identified in blood from patients in renal failure, liver failure, and pregnant women in their third trimester. The presence of DLIS in a sample can result in a false elevation of digoxin when assayed by commercially available immunoassays. Therapeutic antibody fragments against digitalis (e.g. DigiFab, DigiBind) will interfere with digitalis immunoassay measurements. Obtain samples prior to antidote administration and note that concentrations may be falsely elevated until the Fab fragments are eliminated from the body. Uzara, nabumetone, hydrocortisone, pentoxifylline and canrenone may cause falsely elevated digoxin values at concentrations of the recommended daily dose. In rare cases, interference due to extremely high titres of antibodies to analyte-specific antibodies, streptavidin or ruthenium can occur. These effects are minimized by suitable test design. Results should always be assessed in conjunction with the patient’s medical history, clinical examination and other findings. |
|
Reference range |
Recommended* therapeutic range 0.6 - 1.2 µg/L Source: Roche Cobas® Digoxin kit insert 2022-05, V6.0 Note that toxicity can occur within the usual therapeutic range. Hypokalaemia, hypomagnesaemia and hypercalcaemia can all increase the risk of toxicity. |
|
Turnaround time |
One working day |
|
Enquiries |
Biochemistry (Automation) |